Author:
Nishikawa Mana,Shimada Noriaki,Kurahashi Motoyasu,Watanabe Kentaro,Kanzaki Motoko,Fukuoka Kosuke,Asano Kenichiro
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Marinos CD. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4:557–67.
2. Kazumoto I, Mayumi S, Kandai N, Rintaro M, Nao T, Koichi K, Kenichiro M, Kunihiko A, Koichi N, Yoshiyuki O, Shori T, Ryojiro T, Hiroshi K, Hidefumi N, Kenji I, Shuichi I, Yasuo O. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273–81.
3. Jennifer CR, Mark H, Heather NR. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12:677–86.
4. Hitoshi S, Krzysztof K, Jan N, Zina M, Andrew BH, Matthew BR, Robert JW, Francesco S, Jiri M, Ali GG, Bruce AJ. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.
5. de la Torre I, Leandro MJ, Edwards JC, Cambridge G. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab. Clin Exp Rheumatol. 2012;30:554–60.